K H Antman

1.3k total citations
23 papers, 994 citations indexed

About

K H Antman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, K H Antman has authored 23 papers receiving a total of 994 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Hematology. Recurrent topics in K H Antman's work include Sarcoma Diagnosis and Treatment (8 papers), Vascular Tumors and Angiosarcomas (4 papers) and Occupational and environmental lung diseases (4 papers). K H Antman is often cited by papers focused on Sarcoma Diagnosis and Treatment (8 papers), Vascular Tumors and Angiosarcomas (4 papers) and Occupational and environmental lung diseases (4 papers). K H Antman collaborates with scholars based in United States. K H Antman's co-authors include Louise Ryan, Anthony Elias, Alby Elias, Holcombe E. Grier, Deborah Witt Sherman, Aarón Sulkes, Jerry M. Collins, David M. Livingston, George D. Demetri and Rosemary Mazanet and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

K H Antman

23 papers receiving 952 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K H Antman United States	15	651	485	178	151	147	23	994
Nicholas Papadopolous United States	10	643 1.0×	499 1.0×	128 0.7×	211 1.4×	136 0.9×	11	1.0k
G. Beron Germany	10	797 1.2×	380 0.8×	226 1.3×	221 1.5×	145 1.0×	17	1.0k
A. Brach del Prever Italy	9	573 0.9×	232 0.5×	170 1.0×	148 1.0×	129 0.9×	16	758
R. S. Benjamin United States	12	665 1.0×	393 0.8×	104 0.6×	154 1.0×	204 1.4×	23	1.1k
Luca Tavecchio Italy	18	696 1.1×	404 0.8×	218 1.2×	87 0.6×	129 0.9×	52	1.2k
Hs Koops Netherlands	14	312 0.5×	284 0.6×	219 1.2×	63 0.4×	46 0.3×	24	737
Esma Saâda France	15	506 0.8×	392 0.8×	166 0.9×	93 0.6×	110 0.7×	70	874
F. J. Pardo-Mindán Spain	14	601 0.9×	186 0.4×	218 1.2×	199 1.3×	196 1.3×	31	935
Marilena Cesari Italy	20	882 1.4×	334 0.7×	227 1.3×	177 1.2×	123 0.8×	63	1.1k
Eisei Ishikawa Japan	19	424 0.7×	500 1.0×	272 1.5×	59 0.4×	369 2.5×	51	1.4k

Countries citing papers authored by K H Antman

Since Specialization

Citations

This map shows the geographic impact of K H Antman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K H Antman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K H Antman more than expected).

Fields of papers citing papers by K H Antman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K H Antman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K H Antman. The network helps show where K H Antman may publish in the future.

Co-authorship network of co-authors of K H Antman

This figure shows the co-authorship network connecting the top 25 collaborators of K H Antman. A scholar is included among the top collaborators of K H Antman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K H Antman. K H Antman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldberg, Mark A., Lidia Schapira, Bernard J. Ransil, et al.. (2015). Erythropoietin Gene Regulation: From the Laboratory to the Bedside. Contributions to nephrology. 88. 35–47. 2 indexed citations

Antman, K H. (2001). Overview of the Six Available Randomized Trials of High-Dose Chemotherapy With Blood or Marrow Transplant in Breast Cancer. JNCI Monographs. 2001(30). 114–116. 3 indexed citations

Ayello, Janet, Robert F. Reiss, Andrea B. Troxel, et al.. (1999). CD34+ Cell Dose Requirements for Rapid Engraftment in a Sequential High-Dose Chemotherapy Regimen of Paclitaxel, Melphalan, and Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) with PBPC Support in Metastatic Breast Cancer. Journal of Hematotherapy & Stem Cell Research. 8(4). 357–363. 3 indexed citations

Elias, AD, Catherine Wheeler, Lois Ayash, et al.. (1998). Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.. PubMed. 4(6). 1443–9. 4 indexed citations

Elias, Anthony, C Wheeler, I Tepler, et al.. (1994). High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.. PubMed. 21(5 Suppl 12). 83–5. 4 indexed citations

Antman, K H. (1993). Natural History and Epidemiology of Malignant Mesothelioma. CHEST Journal. 103(4). 373S–376S. 105 indexed citations

Kaplan, William D., et al.. (1992). Gallium imaging in metastatic and recurrent soft-tissue sarcoma.. PubMed. 33(9). 1594–9. 22 indexed citations

Antman, K H. (1992). Chemotherapy of advanced sarcomas of bone and soft tissue.. PubMed. 19(6 Suppl 12). 13–20. 28 indexed citations

Antman, K H. (1991). G-CSF and GM-CSF in clinical trials.. PubMed. 63(5). 387–410. 13 indexed citations

10.

Mazanet, Rosemary & K H Antman. (1991). Adjuvant therapy for sarcomas.. PubMed. 18(6). 603–12. 29 indexed citations

11.

Elias, Anthony & K H Antman. (1989). Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen.. PubMed. 16(4). 305–11. 47 indexed citations

12.

Elias, Anthony, et al.. (1989). Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.. Journal of Clinical Oncology. 7(9). 1208–1216. 207 indexed citations

13.

Antman, K H, et al.. (1989). Soft tissue sarcomas: Current trends in diagnosis and management. Current Problems in Cancer. 13(6). 340–369. 32 indexed citations

14.

Antman, K H, Louise Ryan, Alby Elias, Deborah Witt Sherman, & Holcombe E. Grier. (1989). Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.. Journal of Clinical Oncology. 7(1). 126–131. 201 indexed citations

15.

Elias, Anthony & K H Antman. (1988). Adjuvant Chemotherapy for Soft‐Tissue Sarcoma: A Critical Appraisal. Seminars in Surgical Oncology. 4(1). 59–65. 8 indexed citations

16.

Recht, A., et al.. (1988). Combined modality treatment of peritoneal mesotheliomas.. PubMed. 321–2. 4 indexed citations

17.

Elias, Alby & K H Antman. (1986). Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.. PubMed. 70(7). 827–33. 20 indexed citations

18.

Kobzik, Lester, K H Antman, & Michael J. Warhol. (1985). The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.. PubMed. 29(3). 219–25. 21 indexed citations

19.

Antman, K H, et al.. (1983). Peritoneal mesothelioma: natural history and response to chemotherapy.. Journal of Clinical Oncology. 1(6). 386–391. 63 indexed citations

20.

Antman, K H & David M. Livingston. (1980). Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell. 19(3). 627–635. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact